Zealand Pharma

News

Zealand forges obesity alliance with AI specialist Generate

Zealand has added another strand to its programme of weight-loss drug development, linking with AI player Generate on multispecific protein therapies.

News

New diabetes and obesity studies making waves at EASD

As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.

News

AZ's gMG drug Klygefa nears EU approval

AstraZeneca's generalised myasthenia gravis (gMG) therapy Klygefa gets CHMP recommendation, alongside several other novel medicines.

News

ADA: Lilly's weight-loss reveal, and wannabes display wares

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

News

ADA: Safety data offset efficacy for survodutide

New data with Zealand/Boehringer's survodutide reinforce its metabolic benefits, but a high discontinuation rate has raised concerns.

News

Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.

Zealand forges obesity alliance with AI specialist Generate

New diabetes and obesity studies making waves at EASD

AZ's gMG drug Klygefa nears EU approval

ADA: Lilly's weight-loss reveal, and wannabes display wares

ADA: Safety data offset efficacy for survodutide

Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

Zealand Pharma

Editor's Picks